Adi Pharmaceutical announced that the company and its wholly-owned subsidiary Luzhou Adi Pharmaceutical Technology Co., Ltd. recently received the “Drug Clinical Trial Approval Notice” approved and issued by the State Drug Administration, agreeing to conduct clinical trials of ACC085 tablets of the new Class 1 drug independently developed by the company for pre-exposure prophylaxis for adults at risk of HIV-1 infection and young people weighing at least 35 kg. ACC085 tablets and ACC085 injections, which have been clinically approved in the early stages, are different dosage forms with the same active ingredient.
Zhitongcaijing · 3d ago
Share
Listen to the news
Adi Pharmaceutical announced that the company and its wholly-owned subsidiary Luzhou Adi Pharmaceutical Technology Co., Ltd. recently received the “Drug Clinical Trial Approval Notice” approved and issued by the State Drug Administration, agreeing to conduct clinical trials of ACC085 tablets of the new Class 1 drug independently developed by the company for pre-exposure prophylaxis for adults at risk of HIV-1 infection and young people weighing at least 35 kg. ACC085 tablets and ACC085 injections, which have been clinically approved in the early stages, are different dosage forms with the same active ingredient.
Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending